![Chris de Jonghe](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chris de Jonghe
Director/Board Member at FORMAC Pharmaceuticals NV
Chris de Jonghe active positions
Companies | Position | Start | End |
---|---|---|---|
Participatiemaatschappij Vlaanderen NV
![]() Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Private Equity Investor | 2012-11-30 | - |
FORMAC Pharmaceuticals NV
![]() FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium. | Director/Board Member | - | - |
FlandersBio vzw
![]() FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Corporate Officer/Principal | - | - |
Vesalius Biocapital I SA SICAR
![]() Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Director/Board Member | - | - |
Vesalius Biocapital II SA SICAR
![]() Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Director/Board Member | - | - |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Director/Board Member | - | - |
Oncode BV
![]() Oncode BV Investment ManagersFinance Oncode BV is a venture capital firm, a subsidiary of Oncode Institute, founded in 2018. Oncode BV is headquartered in Utrecht. | Corporate Officer/Principal | 2020-04-30 | - |
Career history of Chris de Jonghe
Former positions of Chris de Jonghe
Companies | Position | Start | End |
---|---|---|---|
CELYAD ONCOLOGY SA | Director/Board Member | 2012-12-31 | 2017-05-04 |
Independent Dir/Board Member | 2015-06-01 | 2017-05-04 | |
reMYND NV
![]() reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Director/Board Member | - | - |
░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░░ ░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of Chris de Jonghe
University of Antwerp | Doctorate Degree |
Statistics
International
Belgium | 13 |
Luxembourg | 3 |
Netherlands | 2 |
Operational
Director/Board Member | 10 |
Corporate Officer/Principal | 2 |
Private Equity Investor | 1 |
Sectoral
Health Technology | 7 |
Finance | 5 |
Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
BIOTALYS NV | Process Industries |
CELYAD ONCOLOGY SA | Health Technology |
Private companies | 12 |
---|---|
Participatiemaatschappij Vlaanderen NV
![]() Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Finance |
eSATURNUS NV
![]() eSATURNUS NV BiotechnologyHealth Technology eSATURNUS NV provides healthcare services for hospitals, doctors, nursing staff, and patients. The company was founded by Thomas Koninckx and Bob Koninckx on April 6, 2007 and is headquartered in Leuven, Belgium. | Health Technology |
Amakem NV
![]() Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Health Services |
FORMAC Pharmaceuticals NV
![]() FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium. | Health Technology |
FlandersBio vzw
![]() FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Commercial Services |
Multiplicom NV
![]() Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Health Technology |
Vesalius Biocapital I SA SICAR
![]() Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
Vesalius Biocapital II SA SICAR
![]() Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
reMYND NV
![]() reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
Oncode BV
![]() Oncode BV Investment ManagersFinance Oncode BV is a venture capital firm, a subsidiary of Oncode Institute, founded in 2018. Oncode BV is headquartered in Utrecht. | Finance |
- Stock Market
- Insiders
- Chris de Jonghe
- Experience